Can't Stop, Won't Stop the Search for Relief: Scratching the Surface of Itch and Inflammation in Moderate-to-Severe AD – Twitter Chat #2 Evaluation (ID: i769-8) Survey

Once you complete and submit the evaluation, please be sure to select your credit amount and click “Continue to Certificates” to claim credit.

Question Title

* 1. Please select the option that best describes your profession:

Dermatologist

Allergist

Internal Medicine

Fellow

Other (please specify)

Question Title

* 2. Please select the option that best describes your practice setting:

Academic medical center

Community hospital or medical center

VA, DOD or other government

Managed Care

Research

Pharmaceutical industry

Question Title

* 3. How many years have you been in practice?

>21

11-20

1-10

Question Title

* 4. How many patients with AD do you manage each week?

1 to 5

6 to 10

>11

I am not directly involved in patient care

Question Title

* 5. After participating in this activity, how confident are you in the management of patients with AD in your practice?

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 6. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Improved diagnosis/assessment of patients with or at-risk-of AD

Increased understanding of AD disease burden

Understand the rationale for use of mAbs in the treatment of AD

Be aware of the status of emerging mAbs and JAKs being studied in moderate-to-severe AD

Other (please explain)

Question Title

* 7. How committed are you to making changes in your practice based on your participation in this activity?

Very committed

Committed

Neutral

Not committed/do not plan to make changes (please explain)

Question Title

* 8. What barriers do you see to making changes in your practice?

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement, or legal issues

Conflicting guidelines and/or evidence

Patient compliance and/or patient resource barriers

Other (please specify)

Question Title

* 9. Which tools do you find most meaningful in measuring disease severity in patients with AD?

Eczema Area and Severity Index (EASI)

Investigators Global Assessment Scale

Body surface area

Single item numeric 0-10 rating scale of itch

Peak Pruritis Numerical Rating Scale

Patient Global Assessment

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating:

After participating in today’s activity, I am now able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Apply knowledge gained about comorbidities and itch associated with moderate-to-severe AD in order to personalize treatment selection	Apply knowledge gained about comorbidities and itch associated with moderate-to-severe AD in order to personalize treatment selection Strongly agree	Apply knowledge gained about comorbidities and itch associated with moderate-to-severe AD in order to personalize treatment selection Agree	Apply knowledge gained about comorbidities and itch associated with moderate-to-severe AD in order to personalize treatment selection Neutral	Apply knowledge gained about comorbidities and itch associated with moderate-to-severe AD in order to personalize treatment selection Disagree	Apply knowledge gained about comorbidities and itch associated with moderate-to-severe AD in order to personalize treatment selection Strongly disagree
Interpret endpoint results from phase 3 clinical trials comparing the biologic dupilumab with JAK inhibitors	Interpret endpoint results from phase 3 clinical trials comparing the biologic dupilumab with JAK inhibitors Strongly agree	Interpret endpoint results from phase 3 clinical trials comparing the biologic dupilumab with JAK inhibitors Agree	Interpret endpoint results from phase 3 clinical trials comparing the biologic dupilumab with JAK inhibitors Neutral	Interpret endpoint results from phase 3 clinical trials comparing the biologic dupilumab with JAK inhibitors Disagree	Interpret endpoint results from phase 3 clinical trials comparing the biologic dupilumab with JAK inhibitors Strongly disagree

Question Title

* 11. After participating in today’s activity, I am now able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Faculty for this activity was effective	Faculty for this activity was effective Strongly agree	Faculty for this activity was effective Agree	Faculty for this activity was effective Neutral	Faculty for this activity was effective Disagree	Faculty for this activity was effective Strongly disagree
Content was scientifically rigorous and evidence based	Content was scientifically rigorous and evidence based Strongly agree	Content was scientifically rigorous and evidence based Agree	Content was scientifically rigorous and evidence based Neutral	Content was scientifically rigorous and evidence based Disagree	Content was scientifically rigorous and evidence based Strongly disagree
Avoided commercial bias or influence	Avoided commercial bias or influence Strongly agree	Avoided commercial bias or influence Agree	Avoided commercial bias or influence Neutral	Avoided commercial bias or influence Disagree	Avoided commercial bias or influence Strongly disagree

Can't Stop, Won't Stop the Search for Relief: Scratching the Surface of Itch and Inflammation in Moderate-to-Severe AD – Twitter Chat #2 Evaluation (ID: i769-8)

Question Title

* 1. Please select the option that best describes your profession:

Question Title

* 2. Please select the option that best describes your practice setting:

Question Title

* 3. How many years have you been in practice?

Question Title

* 4. How many patients with AD do you manage each week?

Question Title

* 5. After participating in this activity, how confident are you in the management of patients with AD in your practice?

Question Title

* 6. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Question Title

* 7. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 8. What barriers do you see to making changes in your practice?

Question Title

* 9. Which tools do you find most meaningful in measuring disease severity in patients with AD?

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating:

After participating in today’s activity, I am now able to:

Question Title

* 11. After participating in today’s activity, I am now able to:

Question Title

* 12. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 13. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities:

Question Title

* 14. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 1. Please select the option that best describes your profession:

Question Title

* 2. Please select the option that best describes your practice setting:

Question Title

* 3. How many years have you been in practice?

Question Title

* 4. How many patients with AD do you manage each week?

Question Title

* 5. After participating in this activity, how confident are you in the management of patients with AD in your practice?

Question Title

* 6. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Question Title

* 7. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 8. What barriers do you see to making changes in your practice?

Question Title

* 9. Which tools do you find most meaningful in measuring disease severity in patients with AD?

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating:After participating in today’s activity, I am now able to:

Question Title

* 11. After participating in today’s activity, I am now able to:

Question Title

* 12. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 13. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities:

Question Title

* 14. If you indicated that you perceived commercial bias or influence, please describe:

* 10. Please rate your level of agreement by checking the appropriate rating:

After participating in today’s activity, I am now able to: